Publications

Suh M. Cumulative risk assessment of urban air toxics: A pilot study in San Antonio, Texas. Presented in the “Quantitative Cumulative Risk Assessment: Is it Feasible Today?” Society of Toxicology 55th Annual Meeting, New Orleans, LA, March 2016.

Meddings J, Kuhn L, Reichert H. Indwelling urinary catheter awareness, order, and indications in ICUs. Presented at the Society for Healthcare Epidemiology of America (SHEA) Annual Meeting, Atlanta, GA, May 2016.

Meddings J, Reichert H, Smith SN, McMahon LF Jr. How do hospital grades publicly displayed on Medicare’s Hospital Compare website compare to whether a hospital was penalized for readmissions and hospital-acquired conditions? Presented at the Society of General Internal Medicine (SGIM) 2016 Annual Meeting, Hollywood, FL, May 2016.

Pastula S, Hackett J, Coalson J, Jiang X, Villafana T, Fryzek J. Burden of respiratory syncytial virus disease among adults in the United States from 1997 to 2012. Abstract, poster presentation, International Society for Pharmacoeconomics (ISPOR), Washington, D.C., May 2016.

Pastula S, Hackett J, Coalson J, Jiang X, Villafana T, Fryzek J. Burden of respiratory syncytial virus disease among adults in the United States from 1997 to 2012. Abstract, poster presentation, International Society for Influenza and Other Respiratory Virus Diseases (ISIRV) 2016 — Options IX for the Control of Influenza, Chicago, IL, August 2016.

Meddings J, Reichert H, Smith SN, et al. How do patient and community-level measures of patient functional status, social support and socioeconomic status compare in predicting the risk of readmission for pneumonia and heart failure? Presented at the Society of General Internal Medicine (SGIM) 2016 Annual Meeting, Hollywood, FL, May 2016.

Young L, Sacks N, Cyr PL, Sharma A, Dahdal DN. Rates of hospitalization and repeat procedures in patients receiving sodium picosulfate/magnesium citrate bowel preparation prior to colonoscopy. Academy Managed Care Pharmacy Annual Meeting, San Francisco, CA, 2016. Bronze Medal Winner.

Lancet JE, Sacks NC, Cyr PL, Chiarella MT, Louie AC, Cortes JE. VYXEOS™ (CPX-351) increases event-rree survival and time spent out of the hospital in acute myeloid leukemia patients, compared with 7+3 standard of care. Academy of Managed Care & Specialty Pharmacy Annual Meeting, San Francisco CA, April 2016.

Sacks NC, Noone J, Cyr PL, Miller DJ, Chiarella MT, Louie AC. Hospitalizations for older patients with acute myeloid leukemia (AML): High costs and long stays, with and without chemotherapy. Academy Health Annual Research Meetings, Boston, MA, 2016.

Sacks NC, Cyr P, Liu Y, Miller DJ, Chiarella MT, Louie AC. 2016. Burden of acute myeloid leukemia (AML) among older newly-diagnosed patients. Blood 128(22):4780; doi: 10.1182/blood.V128.22.4780.4780.